US Patent

US12414942 — Compositions, methods, and systems for treating presbyopia

Method of Use · Assigned to Lenz Therapeutics Operations Inc · Expires 2044-03-15 · 18y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods for treating presbyopia using an ophthalmological composition, such as one containing aceclidine.

USPTO Abstract

The present disclosure provides methods comprising administration protocols of an ophthalmological composition, such as comprising aceclidine.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3741`	—

Patent Metadata

Patent number: US12414942
Jurisdiction: US
Classification: Method of Use
Expires: 2044-03-15
Drug substance claim: No
Drug product claim: No
Assignee: Lenz Therapeutics Operations Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.